The OpenEvidence Exit From Europe: Why Elna Is the Real Alternative

What happened when OpenEvidence exited Europe?

OpenEvidence, the tool that proved clinicians will adopt AI for real-time evidence retrieval and decision support, withdrew from the European market earlier this year. For the thousands of European clinicians who had already built it into their daily practice, that left a gap: a workflow they'd come to rely on, with nothing European built to replace it.

Filling that gap is ambitious; OpenEvidence is a much larger company than we are. But it's what Elna was built for from the start: a clinical AI grounded in European evidence, for European clinicians, from day one, not retrofitted for the market after the fact. Months of work went into that foundation before the gap ever opened. When it did, thousands of clinicians started relying on Elna in a matter of weeks. That's the clearest sign yet that what we built has real value, not just good timing.

Why did OpenEvidence exit Europe, and is that the right lesson to take?

OpenEvidence, with $700M+ raised and the leading clinical AI tool in the US, cited the EU AI Act's regulatory uncertainty as its reason for exiting Europe. We think that's the wrong lesson to take from it.

High-risk medical AI should meet a high bar before it sits between a clinician and a patient. The EU AI Act, MDR and GDPR aren't a lane to slalom around; they're the floor patient safety in Europe is built on. Shying away from that bar doesn't protect patients, it just leaves the market to whoever's willing to clear it.

Today, Elna is built for evidence retrieval. It helps healthcare professionals search, retrieve and review published medical literature and reference material, and it's scoped so that the clinician remains the one making the call. As the product takes on more, the regulatory requirements that come with it are part of the plan rather than an afterthought, and we're building the knowledge base, the traceability and the governance layer with that in mind. Being built in Europe, for Europe, against European standards is the strategy, not a disadvantage we work around.

What makes Elna different from a US tool retrofitted for Europe?

Elna is built on European medical sources, grounded and traceable answers, and EU-sovereign infrastructure, rather than being a US product adapted for a new market after the fact.

• European medicine isn't a translation problem. A drug approved and dosed one way in the US formulary can carry a different indication, a different contraindication list, or simply not exist under national reimbursement in Spain, Italy, or France. Clinical guidelines diverge by country: NICE isn't SEMI isn't the GPC. A tool built on US sources and machine-translated into European languages gets the words right and the medicine wrong. Elna is built the other way around, with a knowledge base constructed from national formularies (AEMPS, AIFA, and others), country-specific guidelines, and the regulatory outputs of European agencies (EMA and national bodies) from day one.

• Every answer is traceable. Rather than generating a plausible-sounding response, Elna retrieves and grounds every answer in a cited source, so you can check what informed it before you act on it. That's a design choice, not an add-on.

• Built and hosted in Europe. Elna runs on EU-sovereign compute, including Barcelona Supercomputing Center's MareNostrum 5. That matters for the same reason European guidelines matter: data residency and regulatory alignment aren't optional in European healthcare.

Is Elna free, and how is it funded?

Elna's clinician app is free, and unlike OpenEvidence, it isn't funded by advertising.

OpenEvidence's free access to clinicians is supported by advertising on the platform. We don't think that's the right model for a tool clinicians turn to for evidence at the point of care, where the answer on screen should be shaped by the evidence and not by who's paying to be in front of them. Elna's clinician app is free because clinician trust and adoption is the asset we're building; monetization comes from hospitals and institutional partners, not from advertisers competing for a clinician's attention mid-query.

Is clinician adoption at Elna organic?

Yes. Elna's user base doubled the day OpenEvidence left Europe, and grew 10x over the following six weeks, entirely through word of mouth and with no paid marketing.

We didn't buy that growth. Clinicians recommended Elna to colleagues because it worked for them, in their language, against their guidelines. We're not the only team that noticed the gap, so judge us on the thing that actually matters: whether the next answer you get from Elna is grounded in something you'd trust to cite yourself.